Search research articles
Contact Us
Filters
Showing results (181-190 of 192) with videos related to
Page
of 20
Sort By:
British Journal of Cancer
|
August 26, 1998
Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo
T D Bradshaw, D F Shi, R J Schultz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2000
BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin
C Manzotti, G Pratesi, E Menta, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 11, 1999
"Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity
G Schramm, H Kahlert, R Suck, et al.
Journal of Medicinal Chemistry
|
December 14, 2001
Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents
S Mahboobi, H Pongratz, H Hufsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 1, 1992
Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent
H R Hendriks, J Plowman, D P Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 1999
Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society
G Hartung, G Stehle, H Sinn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models
H R Hendriks, P E Pizao, D P Berger, et al.
Pharmeuropa Bio & Scientific Notes
|
January 19, 2013
Establishment of recombinant major allergens Bet v 1 and Phl p 5a as Ph. Eur. reference standards and validation of ELISA methods for their measurement. Results from feasibility studies
S Vieths, D Barber, M Chapman, et al.
European Surgical Research. Europaische Chirurgische Forschung. Recherches Chirurgicales Europeennes
|
January 1, 1997
Processing of tumor tissues for vaccination with autologous tumor cells
M Lahn, G Köhler, C Schmoor, et al.
Molecular Cancer Research : MCR
|
August 13, 2015
Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor
Amelie Forest, Michael Amatulli, Dale L Ludwig, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 192) with videos related to
Sort By:
Page
of 20
British Journal of Cancer
|
August 26, 1998
Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo
T D Bradshaw, D F Shi, R J Schultz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2000
BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin
C Manzotti, G Pratesi, E Menta, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 11, 1999
"Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity
G Schramm, H Kahlert, R Suck, et al.
Journal of Medicinal Chemistry
|
December 14, 2001
Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents
S Mahboobi, H Pongratz, H Hufsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 1, 1992
Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent
H R Hendriks, J Plowman, D P Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 1999
Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society
G Hartung, G Stehle, H Sinn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models
H R Hendriks, P E Pizao, D P Berger, et al.
Pharmeuropa Bio & Scientific Notes
|
January 19, 2013
Establishment of recombinant major allergens Bet v 1 and Phl p 5a as Ph. Eur. reference standards and validation of ELISA methods for their measurement. Results from feasibility studies
S Vieths, D Barber, M Chapman, et al.
European Surgical Research. Europaische Chirurgische Forschung. Recherches Chirurgicales Europeennes
|
January 1, 1997
Processing of tumor tissues for vaccination with autologous tumor cells
M Lahn, G Köhler, C Schmoor, et al.
Molecular Cancer Research : MCR
|
August 13, 2015
Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor
Amelie Forest, Michael Amatulli, Dale L Ludwig, et al.
Page
of 20